Safety, Efficacy of an Accelerated Regimen of Low-Dose Recombinant Tissue-Type Plasminogen Activator for Reperfusion Therapy of Acute Pulmonary Embolism
Controversy persists regarding the safety and efficacy of an accelerated low-dose recombinant tissue-type plasminogen activator (rt-PA) regimen for reperfusion therapy in acute pulmonary embolism. This study describes the outcomes of an accelerated low-dose rt-PA regimen for the treatment of acute p...
Main Authors: | , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2021-09-01
|
Series: | Clinical and Applied Thrombosis/Hemostasis |
Online Access: | https://doi.org/10.1177/10760296211037920 |
id |
doaj-793927a36d8a4229b8a94bd1fa09e8f4 |
---|---|
record_format |
Article |
spelling |
doaj-793927a36d8a4229b8a94bd1fa09e8f42021-09-13T22:33:19ZengSAGE PublishingClinical and Applied Thrombosis/Hemostasis1938-27232021-09-012710.1177/10760296211037920Safety, Efficacy of an Accelerated Regimen of Low-Dose Recombinant Tissue-Type Plasminogen Activator for Reperfusion Therapy of Acute Pulmonary EmbolismBui Hai Hoang MD, PhD0Phuc Giang Do MD, MSc1 Lac Duy Le MD2Thao Thi Huong Bui Pharmacist, MSc3Thinh Nghia Bui MD, MSc4Quan Minh Nguyen MD, PhD5Duong Hoang To MD, MSc6Anh Dat Nguyen MD, PhD7Michael M. Dinh MD, PhD8Samuel Z. Goldhaber MD, PhD9Richard Day10Hieu Lan Nguyen MD, PhD11 , Hanoi, Vietnam Hanoi Medical University Hospital, Hanoi, Vietnam , Hochiminh city, Vietnam , Hanoi, Vietnam , Hochiminh city, Vietnam , Hochiminh city, Vietnam , Hanoi, Vietnam , Hanoi, Vietnam The University of Sydney, , Sydney, New South Wales, Australia Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts, USA UNSW Medicine & St Vincent’s Clinical School, Sydney, New South Wales, Australia , Hanoi, VietnamControversy persists regarding the safety and efficacy of an accelerated low-dose recombinant tissue-type plasminogen activator (rt-PA) regimen for reperfusion therapy in acute pulmonary embolism. This study describes the outcomes of an accelerated low-dose rt-PA regimen for the treatment of acute pulmonary embolism in Vietnamese patients. This was a case series from October 2014 to October 2020 from 9 hospitals across Vietnam. Patients presenting with acute pulmonary embolism with high to intermediate mortality risk were administered alteplase 0.6 mg per kilogram (maximum of 50 mg) over 15 min. The main outcomes were the proportion who survived to hospital discharge and at 3 months as well as in-hospital hemorrhage (major and minor according to International Society of Thrombosis and Hemhorrage definitions). A total of 80 patients were enrolled: 48 (60%) with high risk for mortality and 32 patients (40%) with intermediate risk for mortality. A total of 7 (8.8%) died in hospital. All deaths occurred in the high-risk mortality group. The 73 patients who were discharged alive remained alive at 3 months follow up. During hospitalization, 1 patient (1.3%) suffered major bleeding, and 7 (8.8%) had minor bleeding. An accelerated thrombolytic regimen with alteplase 0.6 mg/kg (maximum of 50 mg) over 15 min for acute pulmonary embolism appeared be effective and safe in a case series of Vietnamese patients.https://doi.org/10.1177/10760296211037920 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Bui Hai Hoang MD, PhD Phuc Giang Do MD, MSc Lac Duy Le MD Thao Thi Huong Bui Pharmacist, MSc Thinh Nghia Bui MD, MSc Quan Minh Nguyen MD, PhD Duong Hoang To MD, MSc Anh Dat Nguyen MD, PhD Michael M. Dinh MD, PhD Samuel Z. Goldhaber MD, PhD Richard Day Hieu Lan Nguyen MD, PhD |
spellingShingle |
Bui Hai Hoang MD, PhD Phuc Giang Do MD, MSc Lac Duy Le MD Thao Thi Huong Bui Pharmacist, MSc Thinh Nghia Bui MD, MSc Quan Minh Nguyen MD, PhD Duong Hoang To MD, MSc Anh Dat Nguyen MD, PhD Michael M. Dinh MD, PhD Samuel Z. Goldhaber MD, PhD Richard Day Hieu Lan Nguyen MD, PhD Safety, Efficacy of an Accelerated Regimen of Low-Dose Recombinant Tissue-Type Plasminogen Activator for Reperfusion Therapy of Acute Pulmonary Embolism Clinical and Applied Thrombosis/Hemostasis |
author_facet |
Bui Hai Hoang MD, PhD Phuc Giang Do MD, MSc Lac Duy Le MD Thao Thi Huong Bui Pharmacist, MSc Thinh Nghia Bui MD, MSc Quan Minh Nguyen MD, PhD Duong Hoang To MD, MSc Anh Dat Nguyen MD, PhD Michael M. Dinh MD, PhD Samuel Z. Goldhaber MD, PhD Richard Day Hieu Lan Nguyen MD, PhD |
author_sort |
Bui Hai Hoang MD, PhD |
title |
Safety, Efficacy of an Accelerated Regimen of Low-Dose Recombinant Tissue-Type Plasminogen Activator for Reperfusion Therapy of Acute Pulmonary Embolism |
title_short |
Safety, Efficacy of an Accelerated Regimen of Low-Dose Recombinant Tissue-Type Plasminogen Activator for Reperfusion Therapy of Acute Pulmonary Embolism |
title_full |
Safety, Efficacy of an Accelerated Regimen of Low-Dose Recombinant Tissue-Type Plasminogen Activator for Reperfusion Therapy of Acute Pulmonary Embolism |
title_fullStr |
Safety, Efficacy of an Accelerated Regimen of Low-Dose Recombinant Tissue-Type Plasminogen Activator for Reperfusion Therapy of Acute Pulmonary Embolism |
title_full_unstemmed |
Safety, Efficacy of an Accelerated Regimen of Low-Dose Recombinant Tissue-Type Plasminogen Activator for Reperfusion Therapy of Acute Pulmonary Embolism |
title_sort |
safety, efficacy of an accelerated regimen of low-dose recombinant tissue-type plasminogen activator for reperfusion therapy of acute pulmonary embolism |
publisher |
SAGE Publishing |
series |
Clinical and Applied Thrombosis/Hemostasis |
issn |
1938-2723 |
publishDate |
2021-09-01 |
description |
Controversy persists regarding the safety and efficacy of an accelerated low-dose recombinant tissue-type plasminogen activator (rt-PA) regimen for reperfusion therapy in acute pulmonary embolism. This study describes the outcomes of an accelerated low-dose rt-PA regimen for the treatment of acute pulmonary embolism in Vietnamese patients. This was a case series from October 2014 to October 2020 from 9 hospitals across Vietnam. Patients presenting with acute pulmonary embolism with high to intermediate mortality risk were administered alteplase 0.6 mg per kilogram (maximum of 50 mg) over 15 min. The main outcomes were the proportion who survived to hospital discharge and at 3 months as well as in-hospital hemorrhage (major and minor according to International Society of Thrombosis and Hemhorrage definitions). A total of 80 patients were enrolled: 48 (60%) with high risk for mortality and 32 patients (40%) with intermediate risk for mortality. A total of 7 (8.8%) died in hospital. All deaths occurred in the high-risk mortality group. The 73 patients who were discharged alive remained alive at 3 months follow up. During hospitalization, 1 patient (1.3%) suffered major bleeding, and 7 (8.8%) had minor bleeding. An accelerated thrombolytic regimen with alteplase 0.6 mg/kg (maximum of 50 mg) over 15 min for acute pulmonary embolism appeared be effective and safe in a case series of Vietnamese patients. |
url |
https://doi.org/10.1177/10760296211037920 |
work_keys_str_mv |
AT buihaihoangmdphd safetyefficacyofanacceleratedregimenoflowdoserecombinanttissuetypeplasminogenactivatorforreperfusiontherapyofacutepulmonaryembolism AT phucgiangdomdmsc safetyefficacyofanacceleratedregimenoflowdoserecombinanttissuetypeplasminogenactivatorforreperfusiontherapyofacutepulmonaryembolism AT lacduylemd safetyefficacyofanacceleratedregimenoflowdoserecombinanttissuetypeplasminogenactivatorforreperfusiontherapyofacutepulmonaryembolism AT thaothihuongbuipharmacistmsc safetyefficacyofanacceleratedregimenoflowdoserecombinanttissuetypeplasminogenactivatorforreperfusiontherapyofacutepulmonaryembolism AT thinhnghiabuimdmsc safetyefficacyofanacceleratedregimenoflowdoserecombinanttissuetypeplasminogenactivatorforreperfusiontherapyofacutepulmonaryembolism AT quanminhnguyenmdphd safetyefficacyofanacceleratedregimenoflowdoserecombinanttissuetypeplasminogenactivatorforreperfusiontherapyofacutepulmonaryembolism AT duonghoangtomdmsc safetyefficacyofanacceleratedregimenoflowdoserecombinanttissuetypeplasminogenactivatorforreperfusiontherapyofacutepulmonaryembolism AT anhdatnguyenmdphd safetyefficacyofanacceleratedregimenoflowdoserecombinanttissuetypeplasminogenactivatorforreperfusiontherapyofacutepulmonaryembolism AT michaelmdinhmdphd safetyefficacyofanacceleratedregimenoflowdoserecombinanttissuetypeplasminogenactivatorforreperfusiontherapyofacutepulmonaryembolism AT samuelzgoldhabermdphd safetyefficacyofanacceleratedregimenoflowdoserecombinanttissuetypeplasminogenactivatorforreperfusiontherapyofacutepulmonaryembolism AT richardday safetyefficacyofanacceleratedregimenoflowdoserecombinanttissuetypeplasminogenactivatorforreperfusiontherapyofacutepulmonaryembolism AT hieulannguyenmdphd safetyefficacyofanacceleratedregimenoflowdoserecombinanttissuetypeplasminogenactivatorforreperfusiontherapyofacutepulmonaryembolism |
_version_ |
1717380219965276160 |